Weight care that treats you, not just a number.

GLP-1 and GLP-1/GIP medications have been used for nearly two decades, originally for type 2 diabetes and more recently for weight management. Research across more than 15,000 patients in the STEP and SURMOUNT trial programs has shown sustained, clinically meaningful weight loss with a manageable side-effect profile. Cardiovascular outcomes data from the SELECT trial showed a roughly 20% reduction in major cardiovascular events in patients with obesity and existing heart disease. No medication is risk-free, but the safety profile is now well-characterized after years of real-world use.Research noteSTEP-1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT trial (NEJM 2023).

The most common are mild and early: nausea, indigestion, constipation, occasional reflux. These almost always improve over the first 4 to 8 weeks as the body adapts and with careful dose titration. Less common but real: gallbladder issues, pancreatitis (rare), and dehydration if vomiting goes unmanaged. Most of the internet anxiety, "Ozempic face" and excessive muscle loss, is really about how fast weight is lost rather than the medication itself. Slower titration, adequate protein, and resistance training mitigate most of these concerns.Research noteSide-effect profiles documented across STEP and SURMOUNT; muscle-mass guidance from the AGA Clinical Practice Update on Pharmacological Interventions for Obesity (2022).

Honest answer: most patients regain a meaningful portion of the weight when GLP-1 medications are stopped abruptly. The STEP-4 extension study showed roughly two-thirds of weight loss returned within a year of discontinuation. This isn't a willpower failure, it's the biology of how these medications work on appetite-regulating hormones. For many patients, obesity is treated more like hypertension: long-term medication is part of long-term control. We discuss this openly from day one so your long-term plan is yours, not imposed.Research noteSTEP-4 extension (JAMA 2022); Obesity Medicine Association position on obesity as a chronic disease.

Some lean-mass loss happens with any significant weight reduction, whether diet, surgery, or medication. With GLP-1s, the proportion of lean mass lost is similar to other methods, typically 20 to 25% of total weight lost. The strategies that protect muscle are well-defined: adequate protein (roughly 1.2 to 1.6 g per kg of goal body weight), resistance training 2 to 3 times per week, and slower titration of the medication. We monitor for this and build it into the plan.Research noteBody composition analyses from SURMOUNT and STEP trials; AGA practice guidance on protein and resistance training during pharmacotherapy.

The FDA-approved threshold for most anti-obesity medications is a BMI of 30 or higher, or 27 with at least one weight-related condition such as diabetes, hypertension, sleep apnea or dyslipidemia. BMI is one screening tool, not the entire picture. Waist circumference, family history, metabolic labs, and overall health context all factor into the right plan. The conversation is always individualized.Research noteFDA labeling for semaglutide, tirzepatide, and combination agents; AACE/ACE Obesity Algorithm.

Yes, and for a real, biological reason. Repeated weight cycling is not a character flaw. It's the body's biological defense of its highest weight, driven by hormones like leptin, ghrelin, and GLP-1 itself. Research has shown that diet alone fails long-term in roughly 80% of patients, not because of weak willpower, but because the body adapts metabolically and hormonally to defend prior weight. Anti-obesity medications work at exactly the level where diets fail: appetite signaling and metabolic adaptation. That's the difference.Research note"Long-term persistence of hormonal adaptations to weight loss" (NEJM 2011); Obesity Society clinical practice guidelines on obesity pharmacotherapy.

These conditions often travel together with obesity, and treating obesity often improves them, sometimes substantially. Many medications used in obesity medicine, especially GLP-1 agonists and metformin, treat both directions at once. The DiRECT trial showed that significant weight loss can lead to remission of type 2 diabetes in a meaningful subset of patients. For PCOS, weight reduction can restore ovulation and improve fertility. We treat these together, not in silos.Research noteDiRECT trial (Lancet 2018); Endocrine Society guidelines on PCOS; ADA Standards of Care in Diabetes.

Most patients see initial weight loss within 4 to 8 weeks. The full medication dose is typically reached over 3 to 5 months through gradual titration, and significant weight loss (10 to 20% of body weight) usually unfolds over 6 to 12 months. Faster is not better. A sustainable rate of about 1 to 2 pounds per week protects muscle, minimizes side effects, and is more likely to last.Research noteTime-to-clinically-meaningful-weight-loss curves from STEP and SURMOUNT; AGA practice update on pharmacotherapy.

Plateaus are expected, not a sign of failure. They typically appear every 6 to 12 weeks as the body adapts metabolically, what researchers call adaptive thermogenesis. Strategies depend on the cause: medication dose adjustment, protein and resistance training tweaks, sleep optimization, addressing a missed thyroid or hormonal driver, or simply patience and trust in the protocol. Plateaus are a normal part of the partnership, not the end of it.Research noteAdaptive thermogenesis is well-characterized in the Obesity Society clinical practice guidelines; AACE Obesity Algorithm includes plateau-management strategies.

For most patients with obesity as a chronic condition, yes, much like treating hypertension or diabetes long-term. The medication is not a 6-month diet pill. Some patients can eventually transition to lower maintenance doses, or off medication entirely while sustaining their loss with lifestyle strategies. Many won't, and that is medically reasonable. The major medical societies, including the Obesity Medicine Association, AACE and the Obesity Society, all recommend treating obesity as a chronic disease that may require ongoing management. We decide the long-term plan together, transparently.Research noteObesity Medicine Association and AACE position statements on chronic disease management; The Obesity Society clinical practice guidelines.

The typical cadence is an intake visit (about 45 minutes), a follow-up at 4 weeks (about 15 minutes) to check tolerance and adjust the dose, then every 3 months thereafter while on therapy. Some patients need closer monitoring early on, for example during fast dose titration, when starting alongside diabetes or blood-pressure medications, or when side effects are active. The schedule flexes with where you are in treatment.

The obesity medicine program is a self-pay practice. The monthly program fee covers physician consultations, prescription management, counseling, and ongoing follow-up, all delivered directly, without going through insurance for visits. Cash and credit card are accepted. The medication itself is billed separately by your pharmacy or through manufacturer cash-pay programs, and insurance coverage for the medication is handled directly with your insurer.

Coverage for anti-obesity medications varies by plan. Some commercial insurers cover medications like Wegovy and Zepbound when documented medical criteria are met; others do not. Medicare currently does not cover anti-obesity drugs purely for weight loss, though coverage may apply for related conditions such as type 2 diabetes (Ozempic, Mounjaro) or obstructive sleep apnea in adults with obesity (Zepbound). Florida Medicaid coverage is also limited. Most patients should plan to verify benefits directly with their insurer before starting.

Yes. Prior authorizations are submitted when a medication requires one and your clinical picture supports it. We document the medical criteria, including BMI, weight-related conditions, prior treatment attempts and lab findings, that insurers typically require for approval of anti-obesity medications.

If coverage is denied, we discuss alternative FDA-approved medications, manufacturer savings programs, and other options. Appeals are pursued when there's a reasonable clinical case. We don't pretend insurance always cooperates, but we work the problem with you.

Yes. Manufacturer cash-pay programs (LillyDirect for Zepbound, NovoCare for Wegovy) are reasonable alternatives for some patients and are discussed openly when relevant. The medication monthly cost through these programs varies; verifying current pricing directly with the manufacturer is recommended before starting.